🇺🇸 FDA

Company profile · Sponsor

Protagonist

Protagonist Therapeutics, Inc

PTGX · NYSE pharma NEWARK, CA, USA
Pipeline
13
Drugs
0
Patents
8

Quick answer

Protagonist (PTGX) is a pharma company. headquartered in NEWARK, CA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker PTGX
Exchange NYSE
Company type pharma
Headquarters NEWARK, CA, USA
SEC CIK 0001377121

Pipeline (13)

Search pipeline →

  1. Open-label rusfertide

    Protagonist

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  2. Placebo

    Protagonist

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  3. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  4. PN-943

    Protagonist

    Ulcerative Colitis Chronic Moderate

    phase 2 small molecule completed

    1 trial

  5. PTG-100

    Protagonist

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  6. PTG-300

    Protagonist

    β-thalassemia

    phase 2 small molecule completed

    2 trials

  7. PTG-300

    Protagonist

    Hereditary Hemochromatosis

    phase 2 small molecule completed

    1 trial

  8. PTG-300

    Protagonist

    Polycythemia Vera

    phase 2 small molecule completed

    2 trials

  9. PN-232

    Protagonist

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  10. PN-235

    Protagonist

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. PN-881 Oral Solution

    Protagonist

    Healthy Volunteer

    phase 1 small molecule active

    1 trial

  12. PTG-100

    Protagonist

    Celiac Disease

    phase 1 small molecule completed

    1 trial

  13. PTG-300

    Protagonist

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12269856

    Hepcidin analogues and uses thereof

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12234300

    Conjugated hepcidin mimetics

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12072338

    Pharmaceutical peptides for the treatment of inflammatory diseases

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12018057

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11939361

    Compositions of peptide inhibitors of Interleukin-23 receptor

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11884748

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11845808

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11840581

    α4β7 thioether peptide dimer antagonists

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Protagonist?

Protagonist (PTGX) is a pharma company. headquartered in NEWARK, CA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Protagonist sponsor?

We track 13 ClinicalTrials.gov-linked programs for Protagonist, including Open-label rusfertide and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Protagonist company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.